Gut Reaction #14: Risankizumab - Targeting interleukin 23 for Crohn’s disease The Lancet recently published results from a study which assessed the efficacy and safety of risankizumab, a monoclonal antibody that targets interleukin-23 only (ustekinumab targets interleukin-21 and 23), in ...